Back to News
Market Impact: 0.15
Kaplan Fox Encourages Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to Contact the Firm Before the Deadline on September 28, 2026 for a Leadership Role
Source: globenewswire.com
Legal & LitigationCompany Fundamentals
A class action lawsuit has been filed against Capricor Therapeutics (NASDAQ: CAPR) on behalf of investors. With no disclosed financial damages or specific allegations in the provided text, the impact is likely limited in the near term, but it adds legal overhang risk for the stock.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.20
Ticker Sentiment
CAPR-0.80
More News
- US Stocks Tumble as Chip Rout Deepens
- Dell stock plunges 11%, leading data center sell-off on concerns about 'enterprise AI timing'
- Bank of America Has 'Accountability' in Face of Fines, Says Moynihan
- Ambani’s Jio seeks to raise $3.2B in what could be India’s biggest IPO
- Travis Kelce joined an activist group pushing Six Flags to consider a sale. The ‘Final Destination’-style death of a patron poured gas on the fire
- Anduril employee tender offer would value the defense tech startup at $90 billion